Organon (OGN) Short-term Investments (2023 - 2024)
Organon (OGN) posted quarterly Short-term Investments of $29.0 million for Q4 2024, up 222.22% year-over-year from $9.0 million in Q1 2024, and up 222.22% on a QoQ basis from $9.0 million in Q4 2023.
Organon (OGN) Short-term Investments (2023 - 2024) Analysis & Trends
Organon has reported Short-term Investments for 2 years, with the latest figure at $29.0 million in Q4 2024.
- Short-term Investments for Q4 2024 came in at $29.0 million, up 222.22% year-over-year; the trailing twelve-month figure through Dec 2024 was $29.0 million (up 222.22% YoY), and the FY2024 annual result was $29.0 million, up 222.22% from the prior year.
- Short-term Investments grew to $29.0 million in Q4 2024, from $9.0 million in the prior quarter.
- Over five years, Short-term Investments peaked at $29.0 million in Q4 2024 and troughed at $9.0 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 29.00 Mn |
| Dec 31, 2023 | 9.00 Mn |